# Study of IBI323 in Patients With Advanced Malignancies

> **NCT04916119** · PHASE1 · UNKNOWN · sponsor: **Innovent Biologics (Suzhou) Co. Ltd.** · enrollment: 322 (estimated)

## Conditions studied

- Advanced Malignancies

## Interventions

- **DRUG:** IBI323

## Key facts

- **NCT ID:** NCT04916119
- **Lead sponsor:** Innovent Biologics (Suzhou) Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-06-29
- **Primary completion:** 2023-06-23
- **Final completion:** 2023-12-09
- **Target enrollment:** 322 (ESTIMATED)
- **Last updated:** 2022-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04916119

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04916119, "Study of IBI323 in Patients With Advanced Malignancies". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT04916119. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*